Biomarkers /
FGF19
Overview
Fibroblast growth factor 19 (FGF19) is a gene that encodes a protein with mitogenic activity that functions as a FGF4 heparin dependent ligand. Missense and silent mutations are observed in cancers such as esophageal cancer, intestinal cancer, and skin cancer.
FGF19 is altered in 4.07% of all cancers with breast invasive ductal carcinoma, invasive breast carcinoma, breast invasive lobular carcinoma, bladder urothelial carcinoma, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in FGF19 are FGF19 Amplification (4.19%), FGF19 Mutation (0.38%), FGF19 Loss (0.06%), FGF19 R127C (0.01%), and FGF19 E125K (0.01%) [3].
Clinical Trials
Significance of FGF19 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.